4Kumar R,Alavi A.Fhorodeoxyghcose-PET in the management of breast cancer[J].Radiol Clin North Am,2004,42(6):1113.
5Vander Hoeven JJ,Hoekstra OS,Comans EF,et al.Determinants of diagnostic performanceof[F-18]fluorodeoxyglucose position emission tomography for axillary staging in breast cancer[J].Ann Surg,2002,236(5):619.
6Eubank WB,Mankof D,Bhattacharya M,et al.Impact of F-DG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer[J].AJR Am J Roentgeno1,2004,183(2):479.
7Marsgall C,Mustafa S,Wheatley DC,et al.A comparison of 18-FDG gamma camera PET mammography and ultrasonography in demonstrating primary disease in locally adavanced breast cancer[J].Nucl Med Coommun,2004,25(7):721.
8Jinnol H,Iked T,Mamli A,et al.Sentinel lymph node biopsy in breast cancer using teehnetium-99m tin colloids 0f diferent size[J].Biomed Pharmacother,2002,56:213.
9Utech C I,Young C S,Winter P F.Prospective evaluation of fluorine 18 fluoredeoxyglucose positron emission tomography in breast cancer for stang of the axilla related to sugery and immunecyteche mistry[J].Eur J Nucl Med,1996,23:1588.
10Adler L P,Faulhaber P F,Schnur K C,et al.Axillary lymph node metastases:screening with(F-18)2 fluorod glucose(FDG)PET[J].Radiology,1997,203:323.
